interestingly they are having a decent run - mostly off the back of MSB momentum: There is definitely a trading strategy for someone who wants exposure to the prospects of the stem cell industry (MSB approval will float all boats) but doesn't want the full brunt of a potential CRL impact (upside will also not be as great as it will be for MSB, but will benefit nonetheless from MSBs success in that scenario).
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-724
-
- There are more pages in this discussion • 369 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.020(2.02%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.01 | 94.3¢ | $4.170M | 4.314M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 116423 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 60061 | 9 |
View Market Depth
| Last trade - 13.57pm 01/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |